logo
logo

Korro Bio Completes $116M Series B Financing To Expand The Frontier Of Genetic Medicine Through Its Pipeline Of Rna Editing Programs

Korro Bio Completes $116M Series B Financing To Expand The Frontier Of Genetic Medicine Through Its Pipeline Of Rna Editing Programs

01/05/22, 12:30 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$116 million
Round Type
series b
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the completion of a $116M Series B financing. This financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease, while expanding its pipeline to address prevalent diseases across multiple therapeutic areas.

Company Info

Company
Korro Bio
Location
cambridge, maryland, united states
Additional Info
Korro Bio is creating transformative therapeutics for patients by selectively editing messenger RNA to recode specific codons to deliver a beneficial change in protein sequence, structure, and function.